Assignee
TRISHULA THERAPEUTICS INC
US·1 granted patent·9 pending applications·0 citations·filing 2018–2025
Top patents by PatentIndex Score
10 records- 0177US2025026850A1Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodiesTRISHULA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0266US2022372163A1Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodiesTRISHULA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0366US2022340680A1Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodiesTRISHULA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0465US2021403593A1Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodiesTRISHULA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 0558US11345757B2Anti-CD39 antibodiesTRISHULA THERAPEUTICS INC·Filed 2018·Granted May 31, 2022·0 cites·7 claims
- 0656US2025188165A1Combinations with an anti human cd39 antibody, an anti human pd-1 antibody, and chemotherapy in gastric cancerTRISHULA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0756US2024150487A1Combinations with an anti human cd39 antibody, an anti human pd-1 antibody, and chemotherapy in gastric cancerTRISHULA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0843US2023242660A1Combination therapy involving anti-cd39 antibodies and anti-pd-1 or anti-pd-l1 antibodiesTRISHULA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 0943US2025129177A1Combination Therapy Involving Anti-CD39 Antibodies and Anti-PD-1 or Anti-PD-L1 AntibodiesTRISHULA THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1039US2023158072A1Combination therapy involving anti-cd39 antibodies and adoptive cell therapyTRISHULA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →